Hologic, Inc. (NASDAQ:HOLX) – Investment analysts at Jefferies Group cut their Q1 2018 earnings per share (EPS) estimates for shares of Hologic in a report issued on Tuesday. Jefferies Group analyst R. Denhoy now expects that the medical equipment provider will post earnings of $0.52 per share for the quarter, down from their prior estimate of $0.54. Jefferies Group currently has a “Buy” rating and a $44.00 target price on the stock. Jefferies Group also issued estimates for Hologic’s Q2 2018 earnings at $0.55 EPS, Q3 2018 earnings at $0.51 EPS, Q4 2018 earnings at $0.52 EPS, FY2018 earnings at $2.10 EPS, FY2019 earnings at $2.34 EPS and FY2020 earnings at $2.61 EPS.

Several other research firms have also issued reports on HOLX. Royal Bank Of Canada restated a “sector perform” rating and issued a $45.00 target price (down previously from $50.00) on shares of Hologic in a report on Wednesday, August 9th. BidaskClub lowered shares of Hologic from a “hold” rating to a “sell” rating in a report on Wednesday, August 9th. Barclays PLC restated an “equal weight” rating and issued a $51.00 target price (down previously from $53.00) on shares of Hologic in a report on Wednesday, August 9th. Needham & Company LLC restated a “buy” rating on shares of Hologic in a report on Tuesday, August 1st. Finally, Zacks Investment Research upgraded shares of Hologic from a “sell” rating to a “hold” rating in a report on Friday, August 4th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and nine have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $47.77.

WARNING: This article was reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/10/11/equities-analysts-issue-forecasts-for-hologic-inc-s-q1-2018-earnings-holx.html.

Shares of Hologic (NASDAQ:HOLX) traded down 0.76% during trading on Wednesday, reaching $36.58. 377,486 shares of the company were exchanged. The stock’s 50 day moving average is $37.73 and its 200 day moving average is $42.02. The company has a market capitalization of $10.26 billion, a price-to-earnings ratio of 13.62 and a beta of 0.91. Hologic has a 1-year low of $35.15 and a 1-year high of $46.80.

Hologic (NASDAQ:HOLX) last issued its earnings results on Wednesday, August 2nd. The medical equipment provider reported $0.50 EPS for the quarter, topping analysts’ consensus estimates of $0.49 by $0.01. The company had revenue of $806.10 million for the quarter, compared to analysts’ expectations of $799.70 million. Hologic had a net margin of 25.65% and a return on equity of 23.18%. The firm’s revenue was up 12.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.51 EPS.

In other news, Director Lawrence M. Levy sold 7,139 shares of the firm’s stock in a transaction dated Thursday, September 7th. The shares were sold at an average price of $39.04, for a total value of $278,706.56. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Lawrence M. Levy sold 7,138 shares of the firm’s stock in a transaction dated Monday, October 9th. The shares were sold at an average price of $37.38, for a total transaction of $266,818.44. The disclosure for this sale can be found here. Insiders sold a total of 25,883 shares of company stock worth $1,035,007 over the last 90 days. Company insiders own 0.79% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in HOLX. Capital World Investors acquired a new stake in Hologic in the 2nd quarter worth approximately $312,441,000. HealthCor Management L.P. acquired a new stake in Hologic in the 2nd quarter worth approximately $76,604,000. Columbus Circle Investors acquired a new stake in Hologic in the 2nd quarter worth approximately $54,511,000. Vanguard Group Inc. boosted its stake in Hologic by 4.2% in the 2nd quarter. Vanguard Group Inc. now owns 29,547,138 shares of the medical equipment provider’s stock worth $1,340,850,000 after purchasing an additional 1,200,825 shares in the last quarter. Finally, Koch Industries Inc. boosted its stake in Hologic by 15,554.1% in the 2nd quarter. Koch Industries Inc. now owns 1,149,481 shares of the medical equipment provider’s stock worth $1,125,000 after purchasing an additional 1,142,138 shares in the last quarter. Institutional investors own 96.38% of the company’s stock.

About Hologic

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Earnings History and Estimates for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.